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Decreased activity of the mitochondrial 2-oxoglutarate dehydrogenase complex (OGDHC) in brain accompanies neurodegener-
ative diseases. To reveal molecular mechanisms of this association, we treated rats with a speciﬁc inhibitor of OGDHC, succinyl
phosphonate, or exposed them to hypoxic stress. In males treated with succinyl phosphonate and in pregnancy-sensitized females
experiencing acute hypobaric hypoxia, we revealed upregulation of brain OGDHC (within 24 hours), with the activity increase
presumably representing the compensatory response of brain to the OGDHC inhibition. This up-regulation of brain OGDHC was
accompaniedbyanincreaseinexploratoryactivityandadecreaseinanxietyoftheexperimentalanimals.Remarkably,thehypoxia-
induced elevation of brain OGDHC and most of the associated behavioral changes were abrogated by succinyl phosphonate.
The antagonistic action of hypoxia and succinyl phosphonate demonstrates potential therapeutic signiﬁcance of the OGDHC
regulation by the phosphonate analogs of 2-oxoglutarate.
1.Introduction
A number of inborn [1–5] and acquired [6–13]n e u -
ropathologies are associated with impaired function of the
mitochondrial 2-oxoglutarate dehydrogenase multienzyme
complex (OGDHC). OGDHC comprises multiple copies of
the three catalytic components: the thiamine diphosphate-
dependent 2-oxoglutarate dehydrogenase (E1o), the lipoyl-
bearing dihydrolipoamide succinyl transferase (E2o), and
the FAD-binding dihydrolipoamide dehydrogenase (E3).
Coupled action of the components is required for an
important regulatory step in the mitochondrial tricarboxylic
acid cycle, the oxidative decarboxylation of 2-oxoglutarate
(Reaction 1, where R = –CH2–CH2–COOH) generating
energy in the form of NADH, and macroergic compound
succinyl-CoA [14]:
HOOC −C = O+H S−CoA + NAD+
O = C ∼S −CoA + CO2 +N ADH+H +
R
R
(1)
To reveal molecular mechanisms of the association
between neuropathologies and OGDHC function, we intro-
duced speciﬁc inhibitors of OGDHC [15], which have
been successfully applied in recent years for cellular [16–
19], tissue [20], and animal [21] studies. Having the2 International Journal of Alzheimer’s Disease
phosphonate residue instead of the leaving carboxyl group
of 2-oxoglutarate, these synthetic inhibitors target the start-
ing and rate-limiting E1o component of OGDHC in a
highly speciﬁc manner, imitating transition state of the
E 1 o - c a t a l y z e ds t e p[ 15, 22]. Hence, application of such
phosphonate analogs of 2-oxoglutarate allows modeling the
states when a decrease in the OGDHC activity is observed.
In particular, such a decrease occurs in brains of patients
with neurodegenerative diseases, including Alzheimer’s [9,
10, 13] and Parkinson’s [6, 11] diseases, Wernicke-Korsakoﬀ
syndrome [12], and progressive supranuclear palsy [8].
It is important to note that 2-oxoglutarate is the gluta-
mate precursor in the glutamate synthesis from glucose de
novo. In view of this, the irreversible degradation of 2-
oxoglutarate by OGDHC (Reaction 1) is intimately related
to the synthesis/degradation of excitatory (glutamate) and
inhibitory(GABA)neurotransmitters.Indeed,theperturbed
ﬂux through the complex was shown to aﬀect the amino
acidlevels[23],whichmayexplainthedevelopmentalimpact
of the OGDHC regulation, shown in our previous paper
[21]. In the present work, we apply the OGDHC inhibitor
succinyl phosphonate to study the behavioral impact of the
OGDHC function in adult rats. We show a compensatory
response of cortex and striatum to the OGDHC inhibition,
which correlates with behavioral changes. Increasing the
inhibition or combining the inhibition with hypoxia may
abrogate the response. The antagonistic action on OGDHC
of the hypoxic stress and synthetic inhibitor is of potential
therapeutic signiﬁcance.
2. Methods
2.1. Animal Experiments. All experiments were performed
with consent to Helsinki Declaration on the Guide for the
Care and Use of Laboratory Animals, deﬁning the conduct
of ethical research on laboratory and other animals. Animals
were kept at 21 ± 2◦C on standard ration and 12/12h
light/dark cycle. Wistar rats of about 200g (males) or 250–
300g (females) were used in the experiment. Pregnant
rats were exposed to hypobaric hypoxia at day 9–10 of
pregnancy by placing in a decompression (altitude) chamber
of 3.3L volume, with a vacuum pump “Mez Mohelnice”
(Mohelnice,CzechRepublic).Acutehypoxiawasachievedby
decreasing the atmospheric pressure in 1min to 145mmHg,
correspondent to 11500m altitude [24]. SP was introduced
to animals at 5 and 25mg/kg by intranasal application of
the water solution of the trisodium salt, with the physiologic
solution substituting for SP in all reference groups. In the
study of the SP inﬂuence on hypoxic eﬀects, the compound
was introduced 45–50min before hypoxic treatment. Exper-
imental groups comprised 6–15 animals.
2.2. Behavioral Parameters. They were estimated in the
standard tests: open-ﬁeld [25], elevated plus maze [26];
light-dark chamber [27], and closed plus maze [28]. Video-
recording and  Easy Track  program [29] were used to
follow behavior. To increase the assessment power, the data
from diﬀerent behavioral tests were analyzed. Diﬀerent tests
were also employed to exclude the animal adaptation to
experimental conditions when the time dependence of the
behavioral changes was studied. The parameters presented
in ﬁgures correspond to those which showed statistically
signiﬁcant changes (P<. 05) and the changes at the level
of trends (P<. 1). The latter provided additional support
for the statistically signiﬁcant changes, thus increasing the
conclusion accuracy.
2.3. Tissue Samples and Enzyme Assay. After physiological
monitoring has been performed, the animals were sacriﬁced
by decapitation; cortex and striatum were excised on ice
quickly, frozen in liquid nitrogen, and stored at −70
◦C
until assay. OGDHC activity was extracted and assayed as
described earlier [21]. Each sample corresponded to one
animal, with the OGDHC assay in a sample repeated 3-
4 times at three diﬀerent protein concentrations. This was
done to ensure that the activity is estimated in the interval
where the dependence of the reaction rate on the catalyst
concentration is linear. Preservation of the linearity at low
and high protein concentrations attests to the absence of
the multienzyme complex dissociation upon dilution and of
the interfering activities consuming the produced NADH,
respectively. The OGDHC activity is expressed as μmol/min
per g of wet tissue.
2.4. Reagents. Succinyl phosphonate was synthesized and
puriﬁed according to published conditions [15]. Halt Pro-
tease Inhibitor Single-Use Cocktail was from “Pierce;” CoA
was from “Gerbu”, Germany, and other chemicals were from
“Sigma,” USA.
2.4.1. Statistical Analysis. It was performed using Statistica
6.0 Software, Inc.. Values are expressed as means ± SEM.
Dispersion of the ratios of the aﬀected to control values (%)
was calculated by taking into account experimental errors in
determination of both values as in [30]. Statistical signiﬁ-
cance of the diﬀerences in the parameter mean values was
testedbyone-wayanalysisofvariance(ANOVA)followedthe
Student-Newman-Keuls post hoc test. Statistical signiﬁcance
ofthediﬀerencesintheanimalstratiﬁcationbytheresistance
to hypoxia was assessed by the Fisher’s exact test.
3. Results
3.1. OGDHC Inhibitor SP Induces Behavioral Changes Con-
comitantly with Up-Regulation of the Brain OGDHC in Male
Rats. Behavior was assessed within 4h (Figure 1) and the
next day (Figure 2) after application of SP. All together, the
results of the open ﬁeld, elevated plus maze and closed
plus maze tests pointed to increased exploratory activity
and decreased anxiety, resulting from the SP application. An
increase in exploratory activity was obvious from statistically
signiﬁcant elevations in the hole inspections (Figure 1(a)),
coming out into light (Figure 1(b)), rearing and crossing the
center (Figure 2). Visits and time per a round in the closed
plus maze showed a trend to decrease (Figure 2), suggesting
improved orientation ability and inspection eﬃciency [28].
Along with the mentioned above increase in the coming outInternational Journal of Alzheimer’s Disease 3
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Figure 1: Changed behavioral parameters of male rats tested in the open ﬁeld (a) and elevated plus maze (b) 4 hours after the treatment
with 5 and 25mg/kg SP. Statistical signiﬁcance: ∗P<. 05; #P ≤ .1.
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Figure 2: Changed behavioral parameters of male rats tested in the
closed plus maze 24 hours after the treatment with 5 and 25mg/kg
SP. Statistical signiﬁcance: ∗P<. 05; #P ≤ .1.
into light (Figure 1), the shorter grooming times (Figures
1(a) and 2) pointed to decreased anxiety. It is noteworthy,
that these eﬀects were not pronounced when the SP-treated
animals were imposed to stress. That is, under stressful con-
ditions of the light-dark chamber, no statistically signiﬁcant
changes in the exploratory activity and anxiety were detected
24h after the treatment (data not shown). Thus, the SP-
induced increases in exploratory activity and risk behavior
do not persist under potentially dangerous conditions when
animal is challenged with a bright light. The diﬀerence of
the animal response to the SP treatment, revealed under
comfortableandstressfulconditions,isindicativeofacertain
adequacy of the response, supporting its behavioral rather
than motoric origin.
Remarkably, increasing SP to 25mg/kg did not always
increase the behavioral eﬀect of 5mg/kg SP, often even
alleviating eﬀects of the low dose (Figures 1 and 2). At
the same time, elevating SP tended to decrease the moving
episodes (Figure 1(a)) and muscle force (data not shown).
It thus appears that at 25mg/kg the systemic action of SP
increases, with the muscle OGDHC inhibition obviously
causing energetic impairment and muscular weakness. This
maycomplicateinterpretationofbehavioralchangesassessed
by the animal movements. Thus, there is a speciﬁc window
of the SP doze where the OGDHC inhibitor increases the
exploratory activity and decreases anxiety of experimental
animals.
After the behavioral parameters were assessed, the ani-
mals were sacriﬁced and the OGDHC activity in the extracts
of cortex and striatum determined (Figure 3). The cortex
activity was increased at 5mg/kg SP, returning to the control
level at 25mg/kg SP (Figure 3(a)). SP also increased the
OGDHCactivityinstriatum(Figure 3(b)),withthemaximal
eﬀect achieved already at a low doze. Thus, increases in the
OGDHC activity of cortex and striatum correlate with the
increased exploratory activity and decreased anxiety of the
animals, as observed under comfortable conditions in the
open ﬁeld, elevated plus maze and closed plus maze tests.
3.2. Protective Action of the SP Preconditioning upon Acute
Hypoxia. In neurodegenerative diseases, the metabolic stress
is often increased by hypoxia, in which damaging action is
associated with the elevated ROS and glutamate excitotoxic-
ity.Incellularexperiments,SPwasshowntoprotectfromthe
glutamate-induced ROS [18] and excitotoxicity [16, 17, 21].
Owing to this, we tested if SP would show a protective action
on the behavioral and biochemical changes induced by
hypoxia. We used the previously established model, in which
acute hypoxia was created in a decompression chamber with4 International Journal of Alzheimer’s Disease
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Figure 3: Inﬂuence of the SP treatment (5 and 25mg/kg) on the cortex (a) and striatum (b) activity of OGDHC in male rats. Statistical
signiﬁcance: ∗P<. 05.
female rats sensitized to the insult by pregnancy [21, 24,
31]. Protective action of SP was observed already during
the acute hypoxia in decompression chamber. Within an
animal group, the resistance to hypoxia assessed by both
physiological and behavioral parameters is known to vary,
deﬁned as low, medium, or high when the time before
collapsing under hypoxic conditions is less than 5 minutes,
between 5 and 10 minutes, and 10 minutes and more,
respectively [24, 32]. Figure 4 shows that pre-conditioning
with a low doze of SP (5mg/kg) increased the percentage of
the highly resistant animals at the expense of the medium
resistant group. The SP-induced increase in the number
of animals highly resistant to hypoxic conditions exhibits
the protective eﬀect of the pretreatment with the OGDHC
eﬀector upon acute hypoxia.
The behavioral eﬀects were determined in the most
reactive low resistant rats 24 hours after recovery from the
hypoxia-induced collapse. Compared to the males assessed
at the same time after the SP treatment (Figure 2), pregnant
females showed more resistance to the action of SP per se
(Figures 5 and 6). That is, SP alone did not signiﬁcantly
inﬂuence the behavioral parameters in the open ﬁeld or
elevated plus maze tests. Only the grooming time was
signiﬁcantly decreased by the low SP doze in both females
(2-fold, Figure 6) and males (3-fold, Figure 2), indicative
of the sex-independent anxiolytic eﬀect of SP on animals.
Remarkably, not only SP, but also hypoxia per se showed an
anxiolytic eﬀect. However, the latter was expressed in the rat
sensitivity to light rather than grooming. That is, hypoxia
caused the statistically signiﬁcant increase in the looking
out into light (Figure 6), with the freezing time tending
to decrease (Figure 5), but did not change the grooming
time (Figure 6). Thus, a certain degree of similarity in the
action of both SP and hypoxia was revealed, although the
common anxiolytic eﬀect was expressed in diﬀerent behav-
ioral parameters, such as grooming or light sensitivity in the
SP or hypoxia treatments, respectively. Noteworthy, the SP
pre-treatment abrogated the hypoxia eﬀects, exposing the
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Figure 4: Inﬂuence of the pre-treatment with 5mg/kg SP on the
resistance of pregnant rats to acute hypobaric hypoxia. Statistical
signiﬁcance: ∗P<. 05.
protective action of SP upon hypoxia. That is, the hypoxia-
induced changes in the locomotor activity and freezing
time were abolished in the SP-treated animals (Figure 5),
as was the statistically signiﬁcant increase in the looking
out into light (Figure 6). Analysis of the OGDHC activity
in cortex of pregnant females provided further evidence on
the SP-induced protection from the hypoxic eﬀects. As seen
from Figure 7, hypoxia increased the OGDHC activity in
cortex,whereaspre-treatmentwithSPreturnedtheOGDHC
activity to the control level. The data of Figure 7 also support
the conclusion that the OGDHC activity level correlates
with behavioral parameters. That is, the hypoxia-induced
behavioral eﬀects (Figures 5 and 6) were accompanied by
the up-regulation of the cortex OGDHC, with the combinedInternational Journal of Alzheimer’s Disease 5
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actionofhypoxiaandSPreturningboththeOGDHCactivity
(Figure 7) and behavioral parameters (Figures 5 and 6) close
to the norm.
Thus, the pre-treatment with a low SP doze (5mg/kg)
normalized the hypoxia-induced changes in the cortex
OGDHC activity (Figure 7) and behavioral parameters (Fig-
ures5and6),increasing the proportion ofrats exhibiting the
high resistance to hypoxia (Figure 4). This means that the
SP pre-treatment protected from hypoxia on biochemical,
behavioral, and physiological levels.
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Figure 7: Inﬂuence of 5mg/kg SP on the elevation in the cortex
activity of OGDHC, induced by acute hypoxia in pregnant rats.
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4. Discussion
In male rats treated with the OGDHC inhibitor SP, we
revealed increased exploratory activity and decreased anxiety
(Figures 1 and 2) concomitant with increases in the OGDHC
activityincortexandstriatum(Figure 3).Thisresultcomple-
ments the known correlation found in human subjects. That
is,theimpairedcognitioninpatientswithneurodegenerative
diseases was observed along with the decreased OGDHC
activity in their brains [7], whereas in animal model we
observe increased exploratory activity with the orientation
and inspection eﬃciency tending to improve (Figures 1 and
2), when the brain OGDHC activity is elevated (Figure 3).
It should be kept in mind that the OGDHC activity
assayedinbrainextractsunderstandardtestconditionsisnot
equaltotheﬂuxthroughOGDHCinsidebraincells.Theﬂux
may diﬀer dependent on the cell type, being determined, in
particular, by the substrate concentrations within the cellular
mitochondria, which are most probably diﬀerent from those
in the standard assay system in vitro. However, the activity
assays do show that (i) application of SP induces the brain
response at the level of the OGDHC regulation, and (ii) the
response is to up-regulate OGDHC, obviously compensating
for the enzyme inhibition by SP. The compensatory response
of brain to the OGDHC inhibition by SP (Figure 3)m a y
occur through activation of internal mechanisms of the
OGDHC stimulation, for example, by protein-protein inter-
actions, posttranslational modiﬁcations, increased synthesis.
In particular, increased synthesis of the ﬁrst component
of OGDHC, E1o, was observed in response to the acute
ethanol-induced stress [33]. Besides, in addition to its action
as the reversible OGDHC inhibitor [15], SP is a protector of
OGDHC from an irreversible inactivation occurring in the
course of catalysis [16, 17]. During a certain time period,
t h i sp r o t e c t i v ee ﬀect may manifest itself as an apparent
increase in the OGDHC activity compared to the control
value with the unprotected enzyme (Figure 3). It cannot,
however, be the only reason for the increase, as the latter may6 International Journal of Alzheimer’s Disease
beobservedintheabsenceofSPaswell.Thatis,theOGDHC
activity of cortex increases also as a result of acute hypoxia in
pregnant rats (Figure 7). Worth noting, also in this case the
elevationoftheOGDHCactivityincortexisaccompaniedby
increased exploratory activity and decreased anxiety (Figures
5 and 6).
In our earlier work on the developmental impact of
the brain OGDHC activity, we observed the sex-determined
diﬀerences in the brain OGDHC expression and reactivity
to SP [21]. The present study conﬁrms dependence of the
behavioral impact of the OGDHC regulation on the animal
physiology, as behavior of pregnant females is less responsive
to SP than that of males. Nevertheless, the sex-independent
anxiolyticeﬀectofSPwasalsoobserved,withthelowdozeof
SP decreasing the grooming time in both males (Figures 1(a)
and 2)a n df e m a l e s( Figure 6).
Remarkably, both earlier [21] and here, the SP action
exhibited an interplay with diﬀerent stresses. For instance,
in males, the SP-induced increase in exploratory activity and
decreaseinanxietywerepronouncedonlyundercomfortable
test conditions (Figures 1 and 2), but not under the stress
conditions of the light-dark chamber (data not shown).
Likewise, in pregnant rats exposed to hypoxia, the SP pre-
treatmentabrogatedmostofthehypoxia-inducedbehavioral
changes (Figures 5 and 6). Combination of the hypoxic stress
with SP also reduced the brain OGDHC activity elevated by
hypoxia (Figure 7). Our data thus point to the antagonistic
action of stress and SP at both biochemical and behavioral
levels. This antagonism could be used to protect from the
negativeeﬀectsofthemetabolicstress.Inparticular,weshow
the protection in the hypoxic model, where SP not only
normalized the behavioral parameters (Figures 5 and 6)a n d
OGDHC activity in cortex (Figure 7), but also increased the
proportion of rats highly resistant to hypoxia (Figure 4).
Earlier, we suggested that metabolic stress accompanying
the onset of neurodegeneration increases an irreversible
inactivation of OGDHC [34, 35], which may also lead in
appearance of aberrant enzyme forms with an elevated abil-
ity to catalyze hazardous side reactions [36]. This irreversible
damage of the OGDHC function occurring in neurode-
generative diseases [7, 36] may be alleviated through the
reversibleinhibitionofOGDHCbySPduetoseveralreasons.
First of all, the inhibition by SP may induce compensatory
eﬀects up-regulating OGDHC (Figure 3). Furthermore, as
shown earlier, SP binding to the active site protects the
essential groups of enzyme from irreversible modiﬁcations
causing inactivation [16, 17]. The SP binding also prevents
the enzyme from catalysis of the side reactions, including
production of ROS and enzyme-bound radicals irreversibly
damaging OGDHC [18]. The work presented here extends
our previous in vitro and in situ studies to animal experi-
ments, showing that reversible inhibition of OGDHC under
conditions of metabolic stress may indeed normalize both
the behavior (Figures 5 and 6) and brain OGDHC activity
level (Figure 7). It is probable that up-regulation of OGDHC
occurs also in response to its irreversible inactivation upon
initial stages of the neurodegenerative diseases. However,
when the inactivatory conditions persist with the up-
regulated OGDHC not protected, the cellular compensatory
ability is exhausted, eventually resulting in the increasing
damage of the brain mitochondrial metabolism. In contrast,
the protective eﬀects of SP described above would allow cells
to combine the OGDHC up-regulation with the enzyme
protection, which may underlie cellular ability to overcome
metabolic stress.
5. Conclusions
Up-regulation of the brain OGDHC activity correlates
with increased exploratory activity and decreased anxiety.
Compensatory response of brain to metabolic stress may
include up-regulation of OGDHC. The up-regulation under
metabolic stress may be adjusted by reversible inhibition
of OGDHC, normalizing the biochemical and behavioral
deviations.
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